Nuformix (LON:NFX) Issues Earnings Results

Nuformix (LON:NFX) released its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports.

Nuformix Stock Down 14.1 %

NFX opened at GBX 0.07 ($0.00) on Thursday. The firm’s 50 day simple moving average is GBX 0.06 and its two-hundred day simple moving average is GBX 0.10. The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The company has a market capitalization of £598,096.30, a PE ratio of -1.63 and a beta of 1.22. Nuformix has a 1-year low of GBX 0.04 ($0.00) and a 1-year high of GBX 0.34 ($0.00).

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.